XOFLX™ stable cell lines technology and corresponding packaging and producer cell lines offer a simplified high-yielding LVV manufacturing system that lowers costs & improves process consistency.
Earlier this year a group of more than 30 contributors from OXGENE, a WuXi Advanced Therapies company dedicated to providing the industry with Discovery Services including design and engineering of plasmids, viral vectors, and cell lines, completed their manuscript and submitted it to Molecular Therapy: Clinical Methods & Development for review. The manuscript went through peer review process and was accepted August 5th, 2024.
The final article, entitled “Lentiviral vector packaging and producer cell lines yield titres equivalent to the industry-standard four-plasmid process” was published online on August 8th, 2024, and can be accessed here.
Molecular Therapy Methods & Clinical Development is an international, open-access journal that publishes peer-reviewed research on methods, procedures, and translational advances in molecular therapy. The journal focuses on cell and gene therapy, particularly in how these therapies are applied in clinical settings. Key topics include novel gene delivery methods, the use of integrating and non-integrating vectors, gene editing techniques, and the manufacturing of these products under Good Manufacturing Practice (GMP) conditions. The journal also addresses regulatory science and the commercialization of these innovative therapies.
Background
Lentiviral vector (LVV)-based cell and gene therapies offer the potential to cure diseases that currently require lifelong treatment. However, large-scale LVV production is hampered by the need for plasmid transfection, which adds operational complexity and cost. To overcome this, we developed LVV packaging and producer cell lines that reduce or eliminate the need for plasmid transfection.
Our team integrated lentiviral packaging genes and transfer plasmids into cell lines using random and transposase-mediated integration, respectively. Through single-cell isolation and testing, we identified top-performing clones. These clonal cell lines produced LVVs with consistent performance comparable to the industry-standard four-plasmid transfection method.
By simplifying the production process, XOFLX™ stable cell lines technology lowers costs and complexity, making LVV-mediated therapies more accessible to patients.
To learn more about the XOFLXTM stable technology and packaging and producer cell lines, visit our web site or contact us to arrange a time to meet with our technical team.